Biogen Inc. (ETR:IDP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 19.03B |
| Revenue (ttm) | 9.35B |
| Net Income (ttm) | 1.58B |
| Shares Out | n/a |
| EPS (ttm) | 10.80 |
| PE Ratio | 12.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52 |
| Average Volume | 310 |
| Open | 129.50 |
| Previous Close | 130.00 |
| Day's Range | 129.50 - 130.30 |
| 52-Week Range | 125.00 - 220.00 |
| Beta | 0.01 |
| RSI | 41.65 |
| Earnings Date | May 1, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Biogen plans new headquarters at Kendall Common
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a mul...
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stif...
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the effica...
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Decoding Biogen's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ: BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available opti...
How Is The Market Feeling About Biogen?
Biogen's (NYSE: BIIB) short percent of float has risen 3.1% since its last report. The company recently reported that it has 3.88 million shares sold short , which is 2.99% of all regular shares that...
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcar...
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
The National Institute for Health and Care Excellence (NICE) has reaffirmed its stance against recommending Alzheimer’s treatments donanemab and lecanemab for NHS use, citing insufficient cost-effecti...
FDA Accepts Supplemental Biologics License Application for Genentech's Gazyva for the Treatment of Lupus Nephritis
– Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit – – The filing application is based on data from the Phase III REGEN...
What the Options Market Tells Us About Biogen
High-rolling investors have positioned themselves bullish on Biogen (NASDAQ: BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's t...
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight
New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight LEQEMBI (lecanemab) has significant market p...
Biogen, Eisai Alzheimer’s drug sent back for EU nod after safety review
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ: BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side eff...
Biogen Options Trading: A Deep Dive into Market Sentiment
Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ: BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
On Tuesday, Biogen Inc. (NASDAQ: BIIB) and Stoke Therapeutics, Inc. (NASDAQ: STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United St...
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of ...